Explore Pulmonary Fibrosis, Therapy and more!

Read about Galectin Therapeutics receiving a patent allowance from the USPTO for its  lead compound GR-MD-02, a potential treatment of pulmonary fibrosis.

Read about Galectin Therapeutics receiving a patent allowance from the USPTO for its lead compound a potential treatment of pulmonary fibrosis.

Potential IPF and Other Fibrotic Disease Treatments Await Patents

MediciNova Awaits Patent for 2 Potential Treatments for IPF and Other Fibrotic Diseases

Potential IPF and Other Fibrotic Disease Treatments Await Patents

Restarting IPF Treatment OFEV After Disease Exacerbation Might Be Safe, Case Study Suggests - Pulmonary Fibrosis News

Restarting IPF Treatment OFEV After Disease Exacerbation Might Be Safe, Case Study Suggests

Restarting IPF Treatment OFEV After Disease Exacerbation Might Be Safe, Case Study Suggests - Pulmonary Fibrosis News

Germany based Boehringer Ingelheim and France based Inventiva have announced a new multi-year research and drug discovery collaboration and licensing agreement. Under the agreement, Inventiva and Boehringer Ingelheim teams will work on validation of a new therapeutic concept to discover new medicines for treating idiopathic pulmonary fibrosis (IPF) and other fibrotic diseases. The partnership will combine Inventiva’s deep knowledge and proprietary technologies …

Boehringer Ingelheim, Inventiva Collaborate to Find New Idiopathic Pulmonary Fibrosis Treatments

Read about findings from the first year of a national idiopathic pulmonary fibrosis registry in Sweden, indicating a low quality of life among patients.

Explore related topics

IPF is a progressive, fatal lung disease in which the alveoli and the lung tissue are damaged, becoming thick and scarred (fibrosis), leading to severe breathing difficulties and compromising oxygen transfer between the lungs and the bloodstream. IPF is characterized by a shortness of breath that gradually worsens, with respiratory failure being the main cause …

Stem Cell Therapies for IPF Treatment: PFF Issues Concerns

IPF is a progressive, fatal lung disease in which the alveoli and the lung tissue are damaged, becoming thick and scarred (fibrosis), leading to severe breathing difficulties and compromising oxygen transfer between the lungs and the bloodstream. IPF is characterized by a shortness of breath that gradually worsens, with respiratory failure being the main cause …

Sixty-six year old Dan Castner was living life to the fullest when he started experiencing difficulties in breathing. While he worked in the outdoor industry for more than 40 years and was used to biking, climbing, camping, skiing and hiking, in March of 2012 his life completely changed. Castner was diagnosed with Idiopathic Pulmonary Fibrosis (IPF), a disease that deepens the tissue and makes lungs thick, stiff and even scarred.

How Are Idiopathic Pulmonary Fibrosis Treatments Advancing?

Read more on how Idiopathic Pulmonary Fibrosis Treatments are advancing.

6 Non-Pharmacological Pulmonary Fibrosis Treatments #PulmonaryFibrosisNews

6 Non-Pharmacological Pulmonary Fibrosis Tips

6 Non-Pharmacological Pulmonary Fibrosis Treatments

Learn more about IPF and how patients benefit with Pirfenidone treatment.

IPF Patients Benefit from Pirfenidone Treatment

Learn more about IPF and how patients benefit with Pirfenidone treatment.

Trial of AEOL 10150 as Treatment for Lung Radiation Exposure Gets Under Way

Trial of AEOL 10150 as Treatment for Lung Radiation Exposure Gets Under Way

Read about Aeolus Pharmaceuticals starting a trial a new formulation of AEOL 10150 to treat pulmonary fibrosis and radiation-exposed lungs.

Pinterest
Search